|
gptkbp:instanceOf
|
antiviral drug
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AF07
|
|
gptkbp:bioavailability
|
25%
|
|
gptkbp:CASNumber
|
147127-20-6
|
|
gptkbp:category
|
antiretroviral therapy
HIV/AIDS drug
nucleotide analogue
hepatitis B drug
|
|
gptkbp:chemicalClass
|
acyclic nucleoside phosphonate
|
|
gptkbp:combinationTherapy
|
efavirenz/emtricitabine/tenofovir
elvitegravir/cobicistat/emtricitabine/tenofovir
emtricitabine/tenofovir
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to tenofovir
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:eliminationHalfLife
|
17 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1993
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasMolecularFormula
|
C9H14N5O4P
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tenofovir
|
|
gptkbp:interactsWith
|
gptkb:didanosine
gptkb:adefovir
gptkb:atazanavir
|
|
gptkbp:KEGGID
|
D08515
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:MeSH_ID
|
D000068879
|
|
gptkbp:metabolism
|
not significantly metabolized by CYP enzymes
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:patentExpired
|
2017 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
B1 (Australia)
|
|
gptkbp:prodrugOf
|
gptkb:tenofovir_alafenamide
tenofovir disoproxil
|
|
gptkbp:proteinBinding
|
<8%
|
|
gptkbp:PubChem_CID
|
DB00300
464205
CHEMBL1258
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
renal impairment
decreased bone mineral density
|
|
gptkbp:synonym
|
PMPA
|
|
gptkbp:UNII
|
H1J9RNW228
|
|
gptkbp:usedFor
|
HIV infection
chronic hepatitis B
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|